Fenwick Represents Impel NeuroPharma in $80 Million Initial Public Offering

Fenwick represented Impel NeuroPharma, a late-stage pharmaceutical company developing transformative therapies for diseases of the central nervous system, in its initial public offering of 5,333,334 shares of common stock at a price of $15 per share, for total proceeds of $80 million.

The shares began trading on the Nasdaq Global Market under the ticker symbol IMPL. In addition, Impel granted the underwriters a 30-day option to purchase up to an additional 800,000 shares of common stock.

Cowen and Guggenheim Securities acted as joint bookrunning managers for the proposed offering. Wedbush PacGrow acted as lead manager. More information can be obtained from the company's announcement.

Fenwick has served as outside counsel to Impel since its incorporation in 2008, having partnered with the company on its formation, multiple rounds of financings, and strategic intellectual property and licensing matters.

The Fenwick transaction team included corporate partners Alan Smith and Amanda Rose and associates Ryan Mitteness, Steven Jean, Adam Conway, law clerk Angelo Angelino and senior paralegal Ellen Welichko; executive compensation and employee benefits partner Nancy Chen, counsel Nicholas Frey and associate Jonathan Stephenson; and intellectual property partners Daniel Becker and Antonia Sequeira and counsel Charles Cathey.